Evidence-Based Research

CDES Therapeutic Data

Comprehensive therapeutic information for terpenes and cannabinoids with ICD-10 codes, mechanisms of action, and PubMed citations.

ICD-10-CM Codes PubMed Citations Evidence Levels Mechanism of Action

Terpene Therapeutics

Research-backed therapeutic applications for cannabis terpenes. Evidence levels: Clinical (human trials), Preliminary (animal/in vitro), Anecdotal (user reports).

Myrcene

terpene:myrcene

Medical Conditions

Insomnia clinical
G47.0 GABAergic activity enhances sedation
PubMed: 21749363
Chronic Pain clinical
G89.29 Analgesic via opioid receptor modulation
PubMed: 23962879
Inflammation preliminary
R09.89 Inhibits prostaglandin E2 production
PubMed: 26548966
Muscle Spasms preliminary
R25.2 Muscle relaxant properties
Synergies: ,

Limonene

terpene:limonene

Medical Conditions

Anxiety Disorders clinical
F41.9 5-HT1A receptor agonism, anxiolytic
PubMed: 23878109
Depression clinical
F32.9 Dopamine and serotonin modulation
PubMed: 16121510
Gastroesophageal Reflux clinical
K21.0 Neutralizes gastric acid, promotes peristalsis
PubMed: 17936558
Fungal Infections established
B35.9 Disrupts fungal cell membrane
PubMed: 15230963
Synergies: ,

Beta-Caryophyllene

terpene:beta-caryophyllene

Medical Conditions

Chronic Pain clinical
G89.29 CB2 receptor agonist (dietary cannabinoid)
PubMed: 18574142
Inflammatory Bowel Disease clinical
K51.9 Reduces intestinal inflammation via CB2
PubMed: 23622939
Neuropathy preliminary
G62.9 Neuroprotective via CB2 activation
PubMed: 25252936
Arthritis clinical
M13.9 Anti-inflammatory via CB2 pathway
Synergies: ,

Linalool

terpene:linalool

Medical Conditions

Anxiety Disorders clinical
F41.9 GABA-A receptor modulation
PubMed: 20828598
Epilepsy clinical
G40.9 Anticonvulsant via glutamate inhibition
PubMed: 10619381
Burns and Wounds preliminary
T30.0 Promotes tissue regeneration
Alzheimer's Disease preliminary
G30.9 Reduces brain plaques, anti-inflammatory
PubMed: 27633670
Synergies: ,

Alpha-Pinene

terpene:alpha-pinene

Medical Conditions

Asthma clinical
J45.9 Bronchodilator, opens airways
PubMed: 12587690
Cognitive Impairment preliminary
R41.8 Acetylcholinesterase inhibition
PubMed: 16689961
Bacterial Infections established
A49.9 Disrupts bacterial cell membranes
PubMed: 21740426
Synergies: ,
View all 10 terpenes with therapeutic data

Cannabinoid Therapeutics

Research-backed therapeutic applications for cannabinoids including FDA approval status and scheduling information.

THC

Delta-9-Tetrahydrocannabinol
Schedule I (federally), varies by state

Research-Supported Conditions

Chemotherapy-Induced Nausea established
R11.0
CB1 receptor activation in brainstem
HIV/AIDS Wasting Syndrome established
B22.2
Appetite stimulation via CB1
Chronic Pain clinical
G89.29
Modulation of pain pathways via CB1/CB2
Multiple Sclerosis Spasticity clinical
G35
Muscle relaxation via CB1
Common Side Effects: Impaired memory and cognition, Anxiety or paranoia (dose-dependent), Dry mouth, Increased heart rate, Coordination impairment

CBD

Cannabidiol
Schedule V (Epidiolex), otherwise unscheduled (<0.3% THC)

Research-Supported Conditions

Epilepsy (Dravet/Lennox-Gastaut) established
G40.4
Modulates sodium channels, reduces neuronal excitability
Anxiety Disorders clinical
F41.9
5-HT1A agonism, ECS modulation
Chronic Pain clinical
G89.29
Anti-inflammatory, TRPV1 modulation
Insomnia clinical
G47.0
Anxiolytic effects improve sleep onset
Common Side Effects: Fatigue, Diarrhea, Changes in appetite, Elevated liver enzymes (high doses)

CBG

Cannabigerol
Unscheduled

Research-Supported Conditions

Inflammatory Bowel Disease preliminary
K51.9
Reduces intestinal inflammation
Glaucoma preliminary
H40.9
Reduces intraocular pressure
Huntington's Disease preliminary
G10
Neuroprotective
Bacterial Infections (MRSA) preliminary
A49.02
Disrupts bacterial membranes
Common Side Effects: Generally well-tolerated, Dry mouth, Drowsiness at high doses

CBN

Cannabinol
Unscheduled

Research-Supported Conditions

Insomnia anecdotal
G47.0
Mild sedative (THC degradation product)
Pain preliminary
G89.29
Weak CB1/CB2 agonist
ALS (Amyotrophic Lateral Sclerosis) preliminary
G12.21
Delays disease onset in models
Common Side Effects: Drowsiness, Mild sedation
View all 9 cannabinoids with therapeutic data

Medical Disclaimer

This therapeutic data is provided for informational and research purposes only. It does not constitute medical advice. Cannabis products are not FDA-approved for the treatment of most conditions listed here. Always consult with a qualified healthcare provider before using cannabis for medical purposes. Evidence levels reflect the current state of research and may change as new studies are published.

Access the Full Dataset

Download the complete therapeutic data with all conditions, symptoms, and citations.

Terpene Data (JSON) Cannabinoid Data (JSON) View on GitHub